SCHEMBL8935086

SCHEMBL8935086

CCN1CCC(Oc2ccc3c(=O)[nH]cc(C)c3c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.60
HRH3 Q9Y5N1 3/20 0.47
PARP1 P09874 5/20 0.46
MAOA P21397 6/20 0.46
MAOB P27338 6/20 0.46
HRH1 P35367 3/20 0.43
CCR3 P51677 3/20 0.43
KCNH2 Q12809 3/20 0.43
CCR1 P32246 1/20 0.42
FGFR1 P11362 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
ROCK2 O75116 1/20 0.41
PRKACA P17612 1/20 0.41
PRKCD Q05655 1/20 0.41
PRKG1 Q13976 1/20 0.41
PKN1 Q16512 1/20 0.41
PKN2 Q16513 1/20 0.41
AAK1 Q2M2I8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8935088 0.91 ROCK1 (0.58) ROCK1HRH3PARP1MAOAMAOB
SCHEMBL8935101 0.89 MAOA (0.60) ROCK1HRH3PARP1MAOAMAOB
SCHEMBL8935114 0.89 ROCK1 (0.58) ROCK1HRH3PARP1MAOAMAOB
SCHEMBL8935109 0.88 ROCK1 (0.57) ROCK1HRH3PARP1MAOAMAOB
SCHEMBL8935224 0.86 ROCK1 (0.55) ROCK1HRH3PARP1MAOAMAOB
SCHEMBL8935195 0.86 MAOA (0.61) ROCK1HRH3PARP1MAOAMAOB
SCHEMBL8935120 0.86 PARP1 (0.56) ROCK1PARP1MAOAMAOBHRH1
SCHEMBL8935130 0.85 ROCK1 (0.57) ROCK1PARP1MAOAMAOBHRH1
SCHEMBL8935147 0.85 MAOB (0.62) ROCK1HRH3PARP1MAOAMAOB
SCHEMBL8938757 0.84 ROCK1 (0.56) ROCK1PARP1MAOAMAOBHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 ROCK1 8/4885HRH3 3637/4885PARP1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.